Braxia Scientific Corp.
CSE: BRAX, OTCQB: SHRMF
Company Overview
Braxia Scientific Corp., formerly Champignon Brands, is pursuing the development and commercialization of rapid onset treatments capable of improving health outcomes, such as depression and post-traumatic stress disorder (PTSD), as well as substance and alcohol use disorders.
The company acquired ALTMed Capital Corp. in April 2020 to bolster its psychedelics presence with a fully operating ketamine clinic located in Ontario. The clinic has been licensed by Health Canada to dose eligible patients with psilocybin and is the only clinic in the country to perform psilocybin doses with the agency's approval.
The company acquired ALTMed Capital Corp. in April 2020 to bolster its psychedelics presence with a fully operating ketamine clinic located in Ontario. The clinic has been licensed by Health Canada to dose eligible patients with psilocybin and is the only clinic in the country to perform psilocybin doses with the agency's approval.
Financial Highlights
$1,731,390
Revenue (ttm)
$246,872
Gross Profit (ttm)
-$0.08
Diluted EPS (ttm)
Management Team
Dr. Roger S. McIntyre
Chairman & CEO
Mr. Stephen R. Brooks
Chief Financial Officer
Mr. Peter Rizakos
Gen. Counsel
Dr. Joshua Rosenblat
Chief Medical & Scientific Officer
Mr. Jason Wolkove
Chief Information Officer
Key Highlights
Market Capitalization
$2,322,607
Shares Outstanding
79,258,993
Shares Short (% of Float)
()
Insider Ownership
11%